Jutta Stoffers-Winterling
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jutta Stoffers-Winterling has a total of 156 co-authors. Here are the top co-authors by number of shared publications:
Klaus Lieb
Leibniz Institute for Resilience Research, Mainz, Germany
29 shared publicationsBirgit A Völlm
Department of Forensic Psychiatry, Center for Neurology; University Rostock; Rostock Germany
12 shared publicationsMichael Ferriter
11 shared publicationsConor Duggan
10 shared publications- Klaus Lieb
Leibniz Institute for Resilience Research (LIR), Mainz, Germany
8 shared publications Simon Gibbon
8 shared publications
Latest Publications
- Top Cited Papers
- 21 May 2026
- Published by Springer Nature in Nature Reviews Psychology
- Vol. 5 (7) , 458-475
Towards mechanism-focused and scalable resilience interventions
- 21 May 2026
- Published by Springer Nature in Nature Reviews Psychology
- Vol. 5 (7) , 458-475
Top Cited PapersTowards mechanism-focused and scalable resilience interventions
- Open Access
- 13 January 2026
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 69 (1) , e10
Utilization of mental health services during the first year of the COVID-19 pandemic – a systematic review and meta-analysis
Background: The COVID-19 pandemic presented significant challenges to infectious disease management and mental health services (MHS). Service demand and delivery changed due to fear of infection, economic hardships, and the psychological effects of protective measures. This systematic review with meta-analysis aims to quantify these impacts on different mental health service settings. Methods: Comprehensive searches were conducted in PubMed, Embase, and PsycINFO, focusing on studies published from the initial outbreak of COVID-19, starting in November 2019. Studies were included comparing the utilization of mental health inpatient, emergency department (ED), and outpatient services (including telemedicine and medication prescriptions) before and during the COVID-19 pandemic. A random-effects model was employed to estimate pooled effects, with study quality assessed using a modified Newcastle-Ottawa Scale. Results: Among 128 studies, significant decreases in utilization were observed during the initial phase of the pandemic for inpatient services (RR: 0.75, 95% CI: 0.67 to 0.85) and ED visits (RR: 0.87, 95% CI: 0.69 to 1.10). Outpatient services showed a similar decline (RR: 0.78, 95% CI: 0.66 to 0.92), while no significant change was found in psychotropic medication prescriptions (RR: 0.90, CI: 0.77 to 1.05). In contrast, telemedicine utilization increased significantly (RR: 7.57, 95% CI: 3.63 to 15.77). Conclusions: The findings reveal substantial shifts in mental health service utilization during the pandemic, with the largest reductions in inpatient services and significant increases in telemedicine use. These results emphasize the need for flexible healthcare models. Further research is essential to evaluate the consequences of reduced MHS utilization.
- 13 January 2026
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 69 (1) , e10
Open AccessUtilization of mental health services during the first year of the COVID-19 pandemic – a systematic review and meta-analysis
Background: The COVID-19 pandemic presented significant challenges to infectious disease management and mental health services (MHS). Service demand and delivery changed due to fear of infection, economic hardships, and the psychological effects of protective measures. This systematic review with meta-analysis aims to quantify these impacts on different mental health service settings. Methods: Comprehensive searches were conducted in PubMed, Embase, and PsycINFO, focusing on studies published from the initial outbreak of COVID-19, starting in November 2019. Studies were included comparing the utilization of mental health inpatient, emergency department (ED), and outpatient services (including telemedicine and medication prescriptions) before and during the COVID-19 pandemic. A random-effects model was employed to estimate pooled effects, with study quality assessed using a modified Newcastle-Ottawa Scale. Results: Among 128 studies, significant decreases in utilization were observed during the initial phase of the pandemic for inpatient services (RR: 0.75, 95% CI: 0.67 to 0.85) and ED visits (RR: 0.87, 95% CI: 0.69 to 1.10). Outpatient services showed a similar decline (RR: 0.78, 95% CI: 0.66 to 0.92), while no significant change was found in psychotropic medication prescriptions (RR: 0.90, CI: 0.77 to 1.05). In contrast, telemedicine utilization increased significantly (RR: 7.57, 95% CI: 3.63 to 15.77). Conclusions: The findings reveal substantial shifts in mental health service utilization during the pandemic, with the largest reductions in inpatient services and significant increases in telemedicine use. These results emphasize the need for flexible healthcare models. Further research is essential to evaluate the consequences of reduced MHS utilization.
- Open Access
- 12 August 2025
- Published by Taylor & Francis in European Journal of Psychotraumatology
- Vol. 16 (1) , 2517920
Co-RESPOND: a federated network of cohorts on mental health and adversity during the COVID-19 pandemic. Challenges, solutions and recommendations for retrospective data harmonization
Background: The SARS-Cov-2 pandemic was associated with a substantial rise in trauma and stressor exposure. The Co-RESPOND consortium (part of the EU horizon 2020-funded RESPOND project) has been initiated to study the impact on mental health, using longitudinal data of separate international cohorts.Aims: The Co-RESPOND initiative aims to retrospectively harmonize mental health and resilience data of ongoing longitudinal cohort studies at the individual participant level; to create an interoperable network of cohorts within a secure environment; to manage these data along with harmonization products (e.g. transformation procedures and variable dictionaries) according to the FAIR principles; and to keep this network live in order to add new data waves or to be joined by new cohorts.Methods: Data were harmonized retrospectively according to the Maelstrom guidance. A federated data network (FDN) was created using the OBiBa software suite.Results: To date, Co-RESPOND consists of nine European cohorts and one global cohort, including 50,885 individual participants. This paper presents Co-RESPOND as a case study for retrospective harmonization of decentralized data where teams collected and transformed data without prior coordination, facing methodological as well as regulatory challenges. The process of this project is outlined in detail, so it could be applied by other researchers for future projects. Its outcomes and the resulting data harmonization products are presented.Conclusions and outlook: The harmonized data are now ready to be shared with external partners for analyses, and Co-RESPOND is open for more partners to join. Lessons learned throughout the project will be reported, and established classification standards will be recommended for use to generate data sets that are available for joint analyses from the start.Trial registration: ClinicalTrials.gov identifier: NCT04556565.
- 12 August 2025
- Published by Taylor & Francis in European Journal of Psychotraumatology
- Vol. 16 (1) , 2517920
Open AccessCo-RESPOND: a federated network of cohorts on mental health and adversity during the COVID-19 pandemic. Challenges, solutions and recommendations for retrospective data harmonization
Background: The SARS-Cov-2 pandemic was associated with a substantial rise in trauma and stressor exposure. The Co-RESPOND consortium (part of the EU horizon 2020-funded RESPOND project) has been initiated to study the impact on mental health, using longitudinal data of separate international cohorts.Aims: The Co-RESPOND initiative aims to retrospectively harmonize mental health and resilience data of ongoing longitudinal cohort studies at the individual participant level; to create an interoperable network of cohorts within a secure environment; to manage these data along with harmonization products (e.g. transformation procedures and variable dictionaries) according to the FAIR principles; and to keep this network live in order to add new data waves or to be joined by new cohorts.Methods: Data were harmonized retrospectively according to the Maelstrom guidance. A federated data network (FDN) was created using the OBiBa software suite.Results: To date, Co-RESPOND consists of nine European cohorts and one global cohort, including 50,885 individual participants. This paper presents Co-RESPOND as a case study for retrospective harmonization of decentralized data where teams collected and transformed data without prior coordination, facing methodological as well as regulatory challenges. The process of this project is outlined in detail, so it could be applied by other researchers for future projects. Its outcomes and the resulting data harmonization products are presented.Conclusions and outlook: The harmonized data are now ready to be shared with external partners for analyses, and Co-RESPOND is open for more partners to join. Lessons learned throughout the project will be reported, and established classification standards will be recommended for use to generate data sets that are available for joint analyses from the start.Trial registration: ClinicalTrials.gov identifier: NCT04556565.
- Open Access
- 17 July 2025
- Published by Center for Open Science in OSF Preprints
From pre-pandemic to pandemic: Unravelling mental health trajectories in clinical and general population cohorts
Background: The COVID-19 pandemic is often portrayed as a universal mental health crisis, especially in studies lacking pre-pandemic data. Research including pre-pandemic measures nonetheless yields mixed results, making the pandemic’s impact on mental health unclear, particularly when considering differences between general and clinical populations.Aims: This study examined depression and anxiety trajectories from pre-pandemic to peri-pandemic phases in general and clinical populations. It also explored how symptom trajectories varied by sociodemographic and pandemic-related factors.Method: Data from six cohorts in Germany, France, and the Netherlands were pooled within the Co-RESPOND project, comprising 2,796 participants. Cohorts were included based on available pre-pandemic data and at least two peri-pandemic assessments. Anxiety and depression symptoms were assessed using standardized measures and converted to z-scores for cross-cohort comparability. Symptom trajectories were identified using Latent Growth Mixture Modelling, and logistic regressions examined predictors of trajectory membership.Results: Participants had a median age of 42.3 years, with 65.6% being women. In the general population, approximately 80% showed decreasing symptoms, even among those with higher initial severity, while 20% maintained consistently low levels. In the clinical population, approximately half showed improvements from moderate symptom levels, with the remainder exhibiting consistently high or low symptoms. In the general population, divorce/separation and having children predicted more favourable anxiety and depression trajectories, while older age and childcare burden predicted less favourable trajectories. In the clinical population, being in a relationship, older age, and being a man were linked to more favourable anxiety trajectories.Conclusions: This study provides substantial evidence to refute the notion of the COVID-19 pandemic as a universal mental health crisis, showing that most adults across both general and clinical populations experienced stable or improving symptoms. Our findings underscore the need for mental health surveillance and responses that are proportionate and targeted, focusing on groups most at risk.
- 17 July 2025
- Published by Center for Open Science in OSF Preprints
Open AccessFrom pre-pandemic to pandemic: Unravelling mental health trajectories in clinical and general population cohorts
Background: The COVID-19 pandemic is often portrayed as a universal mental health crisis, especially in studies lacking pre-pandemic data. Research including pre-pandemic measures nonetheless yields mixed results, making the pandemic’s impact on mental health unclear, particularly when considering differences between general and clinical populations.Aims: This study examined depression and anxiety trajectories from pre-pandemic to peri-pandemic phases in general and clinical populations. It also explored how symptom trajectories varied by sociodemographic and pandemic-related factors.Method: Data from six cohorts in Germany, France, and the Netherlands were pooled within the Co-RESPOND project, comprising 2,796 participants. Cohorts were included based on available pre-pandemic data and at least two peri-pandemic assessments. Anxiety and depression symptoms were assessed using standardized measures and converted to z-scores for cross-cohort comparability. Symptom trajectories were identified using Latent Growth Mixture Modelling, and logistic regressions examined predictors of trajectory membership.Results: Participants had a median age of 42.3 years, with 65.6% being women. In the general population, approximately 80% showed decreasing symptoms, even among those with higher initial severity, while 20% maintained consistently low levels. In the clinical population, approximately half showed improvements from moderate symptom levels, with the remainder exhibiting consistently high or low symptoms. In the general population, divorce/separation and having children predicted more favourable anxiety and depression trajectories, while older age and childcare burden predicted less favourable trajectories. In the clinical population, being in a relationship, older age, and being a man were linked to more favourable anxiety trajectories.Conclusions: This study provides substantial evidence to refute the notion of the COVID-19 pandemic as a universal mental health crisis, showing that most adults across both general and clinical populations experienced stable or improving symptoms. Our findings underscore the need for mental health surveillance and responses that are proportionate and targeted, focusing on groups most at risk.
- Open Access
- 8 May 2025
- Published by Wiley in Nursing & Health Sciences
- Vol. 27 (2) , e70096
Case Management for Enhancing Wellbeing, Resilience, and Quality of Life in Caregivers of Children and Adolescents With Chronic Illnesses and Disabilities: A Systematic Review and Meta‐Analysis
Caregivers of children and adolescents with chronic illnesses often experience mental health challenges, which increase their risk of poor quality of life. This systematic review evaluates the effectiveness of case management interventions in improving caregivers' positive mental health, psychological distress, and satisfaction with health care services. We included (cluster) randomized controlled trials that evaluated the effects of case management. Systematic searches were conducted in PubMed, Scopus, CENTRAL, and PsycINFO up to 30 June 2024. Risk of bias was assessed using the Cochrane tool (RoB 2), and multi‐level meta‐analyses were performed for post‐intervention outcomes, while follow‐up data were synthesized qualitatively due to limited long‐term evidence. A total of 17 studies were included, providing multiple effect estimates for different types of outcomes, showing small positive effects of case management on mental health (analyses based on 8 studies), psychological distress (6 studies), and satisfaction with health services (9 studies). Although case management interventions show promise in supporting carers, the limited number of studies limits the strength and generalizability of the findings. Further research is needed to explore the long‐term effectiveness of such interventions. Trial Registration: The review protocol was prospectively registered at PROSPERO (CRD4202453375).
- 8 May 2025
- Published by Wiley in Nursing & Health Sciences
- Vol. 27 (2) , e70096
Open AccessCase Management for Enhancing Wellbeing, Resilience, and Quality of Life in Caregivers of Children and Adolescents With Chronic Illnesses and Disabilities: A Systematic Review and Meta‐Analysis
Caregivers of children and adolescents with chronic illnesses often experience mental health challenges, which increase their risk of poor quality of life. This systematic review evaluates the effectiveness of case management interventions in improving caregivers' positive mental health, psychological distress, and satisfaction with health care services. We included (cluster) randomized controlled trials that evaluated the effects of case management. Systematic searches were conducted in PubMed, Scopus, CENTRAL, and PsycINFO up to 30 June 2024. Risk of bias was assessed using the Cochrane tool (RoB 2), and multi‐level meta‐analyses were performed for post‐intervention outcomes, while follow‐up data were synthesized qualitatively due to limited long‐term evidence. A total of 17 studies were included, providing multiple effect estimates for different types of outcomes, showing small positive effects of case management on mental health (analyses based on 8 studies), psychological distress (6 studies), and satisfaction with health services (9 studies). Although case management interventions show promise in supporting carers, the limited number of studies limits the strength and generalizability of the findings. Further research is needed to explore the long‐term effectiveness of such interventions. Trial Registration: The review protocol was prospectively registered at PROSPERO (CRD4202453375).
- Open Access
- 18 April 2025
- Published by Center for Open Science in OSF Preprints
Long-term effects of psychotherapy in children and adolescents: Protocol of a database development and systematic review in the LaKiJu META project
Introduction. Approximately one in every six children and adolescents is affected by mental disorders, which impose significant costs on patients, their families, and societies. Psychotherapy is the first-line treatment for many of these disorders, and systematic reviews of post-intervention effects show small to moderate favorable outcomes compared to control groups. However, the long-term effects of psychotherapy remain less well understood.Methods and analysis. The LaKiJu META project aims to address this gap by developing an open-access database, which will subsequently be used for data synthesis. This database will be established through literature searches in nine databases for (cluster) randomized controlled trials (RCTs) investigating the long-term effects (≥6 months) of any type of psychotherapy in school-aged children and adolescents (ages 6;00 to 17;11 years) with mental disorders. Outcomes will be prioritized based on their relevance to patients, caregivers, and clinicians, and will encompass a broad range of measures, including symptom changes, response rates, and reliable changes. Syntheses will use multilevel meta-analyses to compare intervention and control groups at follow-up assessments, across both transdiagnostic and disorder-specific symptom outcomes. In secondary analyses, we will examine changes within intervention groups over time. Moderator analyses will focus on the effects of study-, intervention-, and patient-level characteristics.Ethics and dissemination. Ethical approval will be obtained for public involvement. For dissemination, we will employ tailored strategies to reach researchers, clinicians, patients and their caregivers, with all groups involved in the development of dissemination plans.Registration details. Preregistered on March 10, 2025, via PROSPERO (ID: CRD420251003208).
- 18 April 2025
- Published by Center for Open Science in OSF Preprints
Open AccessLong-term effects of psychotherapy in children and adolescents: Protocol of a database development and systematic review in the LaKiJu META project
Introduction. Approximately one in every six children and adolescents is affected by mental disorders, which impose significant costs on patients, their families, and societies. Psychotherapy is the first-line treatment for many of these disorders, and systematic reviews of post-intervention effects show small to moderate favorable outcomes compared to control groups. However, the long-term effects of psychotherapy remain less well understood.Methods and analysis. The LaKiJu META project aims to address this gap by developing an open-access database, which will subsequently be used for data synthesis. This database will be established through literature searches in nine databases for (cluster) randomized controlled trials (RCTs) investigating the long-term effects (≥6 months) of any type of psychotherapy in school-aged children and adolescents (ages 6;00 to 17;11 years) with mental disorders. Outcomes will be prioritized based on their relevance to patients, caregivers, and clinicians, and will encompass a broad range of measures, including symptom changes, response rates, and reliable changes. Syntheses will use multilevel meta-analyses to compare intervention and control groups at follow-up assessments, across both transdiagnostic and disorder-specific symptom outcomes. In secondary analyses, we will examine changes within intervention groups over time. Moderator analyses will focus on the effects of study-, intervention-, and patient-level characteristics.Ethics and dissemination. Ethical approval will be obtained for public involvement. For dissemination, we will employ tailored strategies to reach researchers, clinicians, patients and their caregivers, with all groups involved in the development of dissemination plans.Registration details. Preregistered on March 10, 2025, via PROSPERO (ID: CRD420251003208).
- Open Access
- 12 December 2024
- Published by Elsevier in Psychiatry Research
- Vol. 344, 116325
SARS-CoV-2 infection and COVID-19 outcomes across mental disorders and the role of sex: A register-based study from Catalonia
- 12 December 2024
- Published by Elsevier in Psychiatry Research
- Vol. 344, 116325
Open AccessSARS-CoV-2 infection and COVID-19 outcomes across mental disorders and the role of sex: A register-based study from Catalonia
- Open Access
- 21 October 2024
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 226 (4) , 226-237
Pharmacological interventions for co-occurring psychopathology in people with borderline personality disorder: secondary analysis of the Cochrane systematic review with meta-analyses
Background: Medications are commonly used to treat co-occurring psychopathology in persons with borderline personality disorder (BPD)Aims: To systematically review and integrate the evidence of medications for treatment of co-occurring psychopathology in people with BPD, and explore the role of comorbidities.Method: Building on the current Cochrane review of medications in BPD, an update literature search was done in March 2024. We followed the methods of this Cochrane review, but scrutinised all identified placebo-controlled trials post hoc for reporting of non BPD-specific (‘co-occurring’) psychopathology, and explored treatment effects in subgroups of samples with and without defined co-occurring disorders. GRADE ratings were done to assess the evidence certainty.Results: Twenty-two trials were available for quantitative analyses. For antipsychotics, we found very-low-certainty evidence (VLCE) of an effect on depressive symptoms (standardised mean difference (SMD) −0.22, P = 0.04), and low-certainty evidence (LCE) of an effect on psychotic–dissociative symptoms (SMD −0.28, P = 0.007). There was evidence of effects of anticonvulsants on depressive (SMD −0.44, P = 0.02; LCE) and anxious symptoms (SMD −1.11, P < 0.00001; VLCE). For antidepressants, no significant findings were observed (VLCE). Exploratory subgroup analyses indicated a greater effect of antipsychotics in samples including participants with co-occurring substance use disorders on psychotic–dissociative symptoms (P = 0.001).Conclusions: Our findings, based on VLCE and LCE only, do not support the use of pharmacological interventions in people with BPD to target co-occurring psychopathology. Overall, the current evidence does not support differential treatment effects in persons with versus without defined comorbidities. Medications should be used cautiously to target co-occurring psychopathology.
- 21 October 2024
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 226 (4) , 226-237
Open AccessPharmacological interventions for co-occurring psychopathology in people with borderline personality disorder: secondary analysis of the Cochrane systematic review with meta-analyses
Background: Medications are commonly used to treat co-occurring psychopathology in persons with borderline personality disorder (BPD)Aims: To systematically review and integrate the evidence of medications for treatment of co-occurring psychopathology in people with BPD, and explore the role of comorbidities.Method: Building on the current Cochrane review of medications in BPD, an update literature search was done in March 2024. We followed the methods of this Cochrane review, but scrutinised all identified placebo-controlled trials post hoc for reporting of non BPD-specific (‘co-occurring’) psychopathology, and explored treatment effects in subgroups of samples with and without defined co-occurring disorders. GRADE ratings were done to assess the evidence certainty.Results: Twenty-two trials were available for quantitative analyses. For antipsychotics, we found very-low-certainty evidence (VLCE) of an effect on depressive symptoms (standardised mean difference (SMD) −0.22, P = 0.04), and low-certainty evidence (LCE) of an effect on psychotic–dissociative symptoms (SMD −0.28, P = 0.007). There was evidence of effects of anticonvulsants on depressive (SMD −0.44, P = 0.02; LCE) and anxious symptoms (SMD −1.11, P < 0.00001; VLCE). For antidepressants, no significant findings were observed (VLCE). Exploratory subgroup analyses indicated a greater effect of antipsychotics in samples including participants with co-occurring substance use disorders on psychotic–dissociative symptoms (P = 0.001).Conclusions: Our findings, based on VLCE and LCE only, do not support the use of pharmacological interventions in people with BPD to target co-occurring psychopathology. Overall, the current evidence does not support differential treatment effects in persons with versus without defined comorbidities. Medications should be used cautiously to target co-occurring psychopathology.
- 20 October 2023
- Published by Springer Nature in Der Nervenarzt
- Vol. 94 (11) , 1062-1074
S3-Leitlinie Borderline-Persönlichkeitsstörung
Zusammenfassung Die Forschung zum Verständnis und insbesondere zur Behandlung der Borderline-Persönlichkeitsstörung (Borderline-PS) hat in den letzten Jahren erhebliche Fortschritte gemacht, sodass erstmals eine evidenzbasierte deutsche Behandlungsleitlinie erstellt werden konnte. Dieser Beitrag beleuchtet die Entwicklung, die wesentlichen inhaltlichen Schwerpunktsetzungen und die Empfehlungen der Leitlinie: Zunächst werden die Empfehlungen zur Diagnostik vorgestellt, und in diesem Zusammenhang auch die bevorstehenden Änderungen in der 11. Version der internationalen statistischen Klassifikation der Krankheiten und verwandter Gesundheitsprobleme (ICD-11) erläutert. Im Anschluss werden die wichtigsten Empfehlungen zur leitliniengerechten psychotherapeutischen und medikamentösen Behandlung sowie geeigneten Behandlungssettings dargestellt. Schließlich werden die Empfehlungen zu den Themenbereichen „Angehörige“ sowie „Elternschaft und Borderline-PS“ vorgestellt.
- 20 October 2023
- Published by Springer Nature in Der Nervenarzt
- Vol. 94 (11) , 1062-1074
S3-Leitlinie Borderline-Persönlichkeitsstörung
Zusammenfassung Die Forschung zum Verständnis und insbesondere zur Behandlung der Borderline-Persönlichkeitsstörung (Borderline-PS) hat in den letzten Jahren erhebliche Fortschritte gemacht, sodass erstmals eine evidenzbasierte deutsche Behandlungsleitlinie erstellt werden konnte. Dieser Beitrag beleuchtet die Entwicklung, die wesentlichen inhaltlichen Schwerpunktsetzungen und die Empfehlungen der Leitlinie: Zunächst werden die Empfehlungen zur Diagnostik vorgestellt, und in diesem Zusammenhang auch die bevorstehenden Änderungen in der 11. Version der internationalen statistischen Klassifikation der Krankheiten und verwandter Gesundheitsprobleme (ICD-11) erläutert. Im Anschluss werden die wichtigsten Empfehlungen zur leitliniengerechten psychotherapeutischen und medikamentösen Behandlung sowie geeigneten Behandlungssettings dargestellt. Schließlich werden die Empfehlungen zu den Themenbereichen „Angehörige“ sowie „Elternschaft und Borderline-PS“ vorgestellt.
- 28 August 2023
- Published by Springer Nature in Die Psychotherapie
- Vol. 68 (5) , 390-402
S3-Leitlinie Borderline-Persönlichkeitsstörung
- 28 August 2023
- Published by Springer Nature in Die Psychotherapie
- Vol. 68 (5) , 390-402
S3-Leitlinie Borderline-Persönlichkeitsstörung